374 related articles for article (PubMed ID: 28500448)
1. Bone Loss After Denosumab: Only Partial Protection with Zoledronate.
Reid IR; Horne AM; Mihov B; Gamble GD
Calcif Tissue Int; 2017 Oct; 101(4):371-374. PubMed ID: 28500448
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
3. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
Horne AM; Mihov B; Reid IR
Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836
[TBL] [Abstract][Full Text] [Related]
4. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
5. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
6. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
[TBL] [Abstract][Full Text] [Related]
7. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
[TBL] [Abstract][Full Text] [Related]
8. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
9. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab.
Mosali P; Bernard L; Wajed J; Mohamed Z; Ewang M; Moore A; Fogelman I; Hampson G
Calcif Tissue Int; 2014 May; 94(5):553-9. PubMed ID: 24509506
[TBL] [Abstract][Full Text] [Related]
11. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.
Makras P; Appelman-Dijkstra NM; Papapoulos SE; van Wissen S; Winter EM; Polyzos SA; Yavropoulou MP; Anastasilakis AD
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4155-e4162. PubMed ID: 33978745
[TBL] [Abstract][Full Text] [Related]
12. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
13. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
[TBL] [Abstract][Full Text] [Related]
14. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
[TBL] [Abstract][Full Text] [Related]
16. Bone Mass Gains After One Denosumab Injection Followed by Zoledronate.
Everts-Graber J; Lehmann T
J Clin Densitom; 2022; 25(3):293-298. PubMed ID: 35450795
[TBL] [Abstract][Full Text] [Related]
17. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
18. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
19. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a 'real-life' study.
Fraser TR; Flogaitis I; Moore AE; Hampson G
J Endocrinol Invest; 2020 Apr; 43(4):469-475. PubMed ID: 31664706
[TBL] [Abstract][Full Text] [Related]
20. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]